Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 9, 2013, Pages 1177-1184

  Nair, P ^a   Ochkur, S I ^b   Protheroe, C ^b   Radford, K ^a   Efthimiadis, A ^a   Lee, N A ^b   Lee, J J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

asthma; COPD; ELISA; EPX; sputum eosinophils

Indexed keywords

EOSINOPHIL GRANULE PROTEIN; EOSINOPHIL PEROXIDASE;

ADULT; AGED; AIRWAY EOSINOPHILIA; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SPUTUM; SPUTUM LEVEL;

ASTHMA; COPD; ELISA; EPX; SPUTUM EOSINOPHILS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL PEROXIDASE; EOSINOPHILIA; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY TRACT DISEASES; SPUTUM;

EID: 84884986382     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12206     Document Type: Article

References (24)

1. Kelly MM, Leigh R, Jayaram L, Goldsmith CH, Nair P, Hargreave FE,. Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol 2006; 117: 989-994.
2. Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E,. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006; 27: 964-971.
3. Pizzichini M, Pizzichini E, Nair P, Clelland L, Efthimiadis A, Dolovich J, et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteriod in patients without sputum eosinophilia. Can Respir J 1999; 6: 323-330.
4. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
5. Castro M, Mathur S, Hargreave F, Boulet L-P, Xie F, Young J, et al. Reslizumab for Poorly Controlled, Eosinophilic Asthma. Am J Respir Crit Care Med 2011; 184: 1125-1132.
6. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
7. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
8. Pizzichini E, Pizzichini M, Efthimiadis A, Hargreave F, Dolovich J,. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996; 9: 1174-1180.
9. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
10. Jayaram L, Pizzichini MM, Cook RJ, Boulet L-P, Lemière C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-494.
11. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
12. D'Silva L, Hassan N, Wang HY, Kjarsgaard M, Efthimiadis A, Hargreave FE, et al. Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Can Respir J 2011; 18: 144-148.
13. Ochkur SI, Kim JD, Protheroe CA, Colbert D, Moqbel R, Lacy P, et al. The development of a sensitive and specific ELISA for mouse eosinophil peroxidase: assessment of eosinophil degranulation ex vivo and in models of human disease. J Immunol Methods 2012; 375: 138-147.
14. Cockcroft DW, Murdock KY, Kirby J, Hargreave F,. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987; 135: 264-267.
15. Hargreave FE, Nair P,. Point: is measuring sputum eosinophils useful in the management of severe asthma? Yes Chest 2011; 139: 1270-1273.
16. D'Silva L, Neighbour H, Gafni A, Radford K, Hargreave F, Nair P,. Quantitative sputum cell counts to monitor bronchitis: a qualitative study of physician and patient perspectives. Can Respir J 2013; 20: 47-51.
17. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129 (3 Suppl): S9-S23.
18. Nair P, Kjarsgaard M, Armstrong S, Efthimiadis A, O'Byrne PM, Hargreave FE,. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. J Allergy Clin Immunol 2010; 126: 404-406.
19. Nair P,. Eosinophil-targeted treatment of asthma. In:, Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. Waltham: MA Elsevier, 2012; pp. 462-466.
20. Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998; 63: 715-722.
21. Leigh R, Belda J, Kelly MM, Cox G, Squillace DL, Gleich GJ, et al. Eosinophil cationic protein relates to sputum neutrophil counts in healthy subjects. J Allergy Clin Immunol 2000; 106: 593-594.
22. Wassom DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS, et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 1981; 67: 651-661.
23. Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998; 252: 418-425.
24. Nakajima T, Matsumoto K, Suto H, Tanaka K, Ebisawa M, Tomita H, et al. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood 2001; 98: 1127-1134.